Senior

Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions.

Retrieved on: 
Wednesday, March 13, 2024

Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions.

Key Points: 
  • Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions.
  • Villepinte, 11 march 2024: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the strengthening of its management team with two appointments.
  • Christine Allard and Eva Ohlsson have joined the Group as senior Vice-President Public Affairs and Corporate Communications, and Senior Vice President Human Resources respectively.
  • Reporting directly to David Hale, Chief Executive Officer, they will both become members of Guerbet’s Executive Committee.

EQS-News: DOUGLAS Group plans Initial Public Offering (IPO) on Frankfurt Stock Exchange

Retrieved on: 
Wednesday, March 13, 2024

DOUGLAS Group, Europe’s number one omnichannel premium beauty destination, plans a public listing on the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange

Key Points: 
  • DOUGLAS Group, Europe’s number one omnichannel premium beauty destination, plans a public listing on the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange
    IPO would accelerate the debt reduction and decrease the interest expenses of the company, thus enlarging the financial flexibility of the DOUGLAS Group and its further value creation
    Sander van der Laan, CEO DOUGLAS Group: “The DOUGLAS Group is ideally positioned to further capitalize on the large and resilient European premium beauty market.
  • The offering would comprise a public offering to individual and institutional investors in Germany as well as international private placements.
  • Following the completion of the IPO, CVC Capital Partners will continue to hold an indirect majority interest in DOUGLAS Group.
  • In the mid-term, the DOUGLAS Group has the ambition to grow group sales (net) at a CAGR of around 7%.

EQS-News: GRENKE AG: DR MARTIN PAAL APPOINTED AS CHIEF FINANCIAL OFFICER OF GRENKE AG

Retrieved on: 
Wednesday, March 13, 2024

Baden-Baden, March 5, 2024 – The Supervisory Board of GRENKE AG has appointed the current Head of Finance,

Key Points: 
  • Baden-Baden, March 5, 2024 – The Supervisory Board of GRENKE AG has appointed the current Head of Finance,
    Dr Martin Paal, as the Chief Financial Officer effective as of July 1, 2024.
  • Dr Martin Paal, born in 1979, is a proven finance and banking expert.
  • After holding several positions at renowned international consulting firms and DZ Bank, Dr Paal joined GRENKE AG as Vice President Controlling in June 2022.
  • Chair of the Supervisory Board of GRENKE AG Jens Rönnberg WP StB: “Dr Paal has been the acting deputy to Dr Sebastian Hirsch in the Finance department since February 2023.

Notification of managers’ transactions

Retrieved on: 
Wednesday, March 13, 2024

Ørsted A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no.

Key Points: 
  • Ørsted A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no.
  • 596/2014 of transactions related to shares in Ørsted A/S made by persons discharging managerial responsibilities in Ørsted A/S and/or persons closely associated with them.
  • See the transactions of Senior Vice President and Head of Global Stakeholder Relations Ingrid Reumert in the attached PDF document.

EQS-News: Advanced Blockchain AG: Former Cisco Germany CEO Michael Ganser joins peaq Foundation as an Executive ahead of mainnet launch

Retrieved on: 
Wednesday, March 13, 2024

05 March 2024 – Michael Ganser, former CEO of Cisco Germany, has been appointed as an executive of peaq Foundation.

Key Points: 
  • 05 March 2024 – Michael Ganser, former CEO of Cisco Germany, has been appointed as an executive of peaq Foundation.
  • Michael joins at the beginning of a critical growth period for peaq and is a significant value driver for the company."
  • Advanced Blockchain AG is pleased to announce that the peaq team with Michael Ganser will be present at TOKEN 2049 in Dubai next month.
  • Advanced Blockchain remains one of the largest shareholders in EoT Labs GmbH as well as a KREST and PEAQ token holder.

EQS-News: Rentschler Biopharma contributes to nearly 25% of FDA approved biopharmaceuticals in 2023

Retrieved on: 
Wednesday, March 13, 2024

Laupheim, Germany, Milford (MA), USA, and Stevenage, UK, March 6, 2024 – In 2023, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 55 new drugs, 17 of which were biopharmaceuticals.

Key Points: 
  • Laupheim, Germany, Milford (MA), USA, and Stevenage, UK, March 6, 2024 – In 2023, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 55 new drugs, 17 of which were biopharmaceuticals.
  • Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), contributed to four, which equals nearly 25%, of these biopharmaceuticals.
  • For the four newly approved products, Rentschler Biopharma provided support with integrated capabilities, including consulting, regulatory services, process development, technology transfer and manufacturing.
  • Benedikt von Braunmühl, CEO of Rentschler Biopharma, said: “At Rentschler Biopharma, we strive to create value sustainably, together with our client partners, for patients with serious and rare diseases worldwide.

EQS-News: Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Retrieved on: 
Wednesday, March 13, 2024

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Key Points: 
  • Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
    The issuer is solely responsible for the content of this announcement.
  • Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
    Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaboration
    BERKELEY, US – MAINZ, Germany – March 5, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a partnership with Trusted Health Advisors (THA), a market leader in supporting the U.S. launches and management of commercial programs for diagnostic products.
  • In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.
  • The Company currently commercializes its first-generation test in Europe and in select international territories through its flagship product ColoAlert® via partnerships with third-party laboratories.

Notification of managers’ transactions

Retrieved on: 
Wednesday, March 13, 2024

Ørsted A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no.

Key Points: 
  • Ørsted A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no.
  • 596/2014 of transactions related to shares in Ørsted A/S made by persons discharging managerial responsibilities in Ørsted A/S and/or persons closely associated with them.
  • See the transactions of Senior Vice President and President of Region APAC Per Mejnert Kristensen in the attached PDF document.

Ørsted appoints new Group CFO and COO

Retrieved on: 
Wednesday, March 13, 2024

Today, Ørsted’s Board of Directors has appointed Trond Westlie as Ørsted’s next Group Chief Financial Officer (CFO) and member of the Executive Board and the Group Executive Team effective as of 1 April 2024.

Key Points: 
  • Today, Ørsted’s Board of Directors has appointed Trond Westlie as Ørsted’s next Group Chief Financial Officer (CFO) and member of the Executive Board and the Group Executive Team effective as of 1 April 2024.
  • On the same date, Patrick Harnett will join Ørsted’s Group Executive Team as Chief Operational Officer (COO).
  • Trond Westlie has served as Group CFO at A.P.
  • Thomas Thune Andersen, Chair of the Board of Directors of Ørsted A/S, says:
    “On behalf of the Board, I’m very pleased to announce Trond Westlie as our next Group CFO and Patrick Harnett as our next COO.

Ørsted divests share of four US onshore wind farms to Stonepeak

Retrieved on: 
Wednesday, March 13, 2024

Through the partnership with Stonepeak, Ørsted will recycle capital to support its business plan and future value-creating renewable energy projects.

Key Points: 
  • Through the partnership with Stonepeak, Ørsted will recycle capital to support its business plan and future value-creating renewable energy projects.
  • Ørsted has signed a transaction with Stonepeak, a leading alternative investment firm specialising in infrastructure and real assets, whereby Ørsted will divest to Stonepeak an equity ownership stake in a portfolio consisting of four US onshore wind farms with a total capacity of 957 MW.
  • Going forward, Stonepeak will receive 80 % of the cash distributions associated with the projects, while Ørsted will continue to operate the portfolio of assets.
  • Ørsted currently has a portfolio of nearly 6 GW of onshore wind, solar, and battery storage projects in operation and under construction across the US.